quinazolines has been researched along with ly-2157299 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, M; Conteh, AM; Craven, KE; Gore, J; Imasuen-Williams, IE; Korc, M | 1 |
1 other study(ies) available for quinazolines and ly-2157299
| Article | Year |
|---|---|
Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Female; Gene Expression Profiling; Genes, Retinoblastoma; Genetic Predisposition to Disease; Humans; Lapatinib; Lymphangiogenesis; Male; Mice, Transgenic; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta | 2016 |